Sana Biotechnology, Inc.
Sana Biotechnology (Nasdaq: SANA) is a biotechnology company developing engineered cell therapies using ex vivo and in vivo platforms. Its ex vivo platform applies hypoimmune (HIP) genetic modifications to help transplanted cells evade immune rejection, while its in vivo platform uses fusogen-based delivery to modify… From the company’s description.
In fiscal 2025, Sana Biotechnology, Inc. reported a net loss of $244.17M. Operations used $143.83M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sana Biotechnology, Inc. does
In the company’s own words
Sana Biotechnology (Nasdaq: SANA) is a biotechnology company developing engineered cell therapies using ex vivo and in vivo platforms. Its ex vivo platform applies hypoimmune (HIP) genetic modifications to help transplanted cells evade immune rejection, while its in vivo platform uses fusogen-based delivery to modify cells inside the patient. The company’s lead ex vivo candidate, SC451, is an induced pluripotent stem cell-derived pancreatic islet cell therapy being developed for type 1 diabetes; its lead in vivo candidate, SG293, delivers a CD19-directed CAR to T cells for potential treatment of B cell cancers and B cell-mediated autoimmune diseases. Sana also studies UP421, a HIP-modified primary islet cell therapy, in an investigator-sponsored study. The company suspended development of its allogeneic CAR T programs in 2025 to focus on SC451 and SG293. Sana reports its business through two platform areas, ex vivo and in vivo cell engineering, rather than revenue-generating operating segments. It has no products approved for commercial sale. Its website is www.sana.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1770121
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sana Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sana Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sana Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sana Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sana Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”